Posted by Michael Wonder on 21 Jul 2023
AbbVie receives positive CHMP opinion for epcoritamab (Tepkinly) for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma
21 July 2023 - The positive CHMP opinion is supported by results from the EPCORE NHL-1 Phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with non-Hodgkin's lymphoma, including iffuse large B-cell lymphoma.
AbbVie today announced the EMA's CHMP has adopted a positive opinion recommending the granting of conditional marketing authorization for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
